Browsing by Subject "Early cardiovascular risk"
Now showing items 1-1 of 1
-
The Na+K+-ATPase inhibitor marinobufagenin and early cardiovascular risk in humans: a review of recent evidence
(Springer, 2019)Purpose of Review This review synthesizes recent findings in humans pertaining to the relationships between marinobufagenin (MBG), a steroidal Na+/K+-ATPase inhibitor and salt-sensitivity biomarker, and early cardiovascular ...